Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）
Status:
Active, not recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
The trial is prospective, block randomized, open-label, blinded endpoint (PROBE) design.
Patients with acute ischemic stroke, who are eligible for standard intravenous thrombolysis
within 4.5 hours of stroke onset will be randomized 1:1:1 to 0.25mg/kg or 0.40mg/kg
intravenous tenecteplase or 0.9 mg/kg alteplase before all participants undergo endovascular
thrombectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Tiantan Hospital
Collaborators:
Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd The Place Pharmaceutical(Jiangsu) Co., Ltd